AR065688A1 - Conjugados de peptidos antifusogenicos - Google Patents

Conjugados de peptidos antifusogenicos

Info

Publication number
AR065688A1
AR065688A1 ARP080100996A ARP080100996A AR065688A1 AR 065688 A1 AR065688 A1 AR 065688A1 AR P080100996 A ARP080100996 A AR P080100996A AR P080100996 A ARP080100996 A AR P080100996A AR 065688 A1 AR065688 A1 AR 065688A1
Authority
AR
Argentina
Prior art keywords
conjugates
antifusogenic peptides
polypeptide
conjugate
group
Prior art date
Application number
ARP080100996A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR065688A1 publication Critical patent/AR065688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Un conjugado de polipéptidos, donde el conjugado comprende un primer polipéptido seleccionado del grupo de polipéptidos que comprende SEQ ID N°:1 y fragmentos de éste, y un segundo polipéptido seleccionado del grupo de péptidos antifusogénicos. Sedivulga una composicion farmacéutica que comprende el conjugado de polipéptidos de la presente para la elaboracion de un medicamento para el tratamiento de infecciones víricas tales como HIV.
ARP080100996A 2007-03-13 2008-03-11 Conjugados de peptidos antifusogenicos AR065688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07005096 2007-03-13

Publications (1)

Publication Number Publication Date
AR065688A1 true AR065688A1 (es) 2009-06-24

Family

ID=37998311

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100996A AR065688A1 (es) 2007-03-13 2008-03-11 Conjugados de peptidos antifusogenicos

Country Status (17)

Country Link
US (1) US20090143288A1 (es)
EP (1) EP2118125B1 (es)
JP (1) JP5081931B2 (es)
KR (1) KR101182951B1 (es)
CN (1) CN101616929B (es)
AR (1) AR065688A1 (es)
AT (1) ATE530564T1 (es)
AU (1) AU2008226051B2 (es)
BR (1) BRPI0808732A2 (es)
CA (1) CA2679647A1 (es)
CL (1) CL2008000707A1 (es)
ES (1) ES2374962T3 (es)
IL (1) IL199718A0 (es)
MX (1) MX2009009370A (es)
PE (1) PE20090163A1 (es)
TW (1) TW200902544A (es)
WO (1) WO2008110332A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0913385D0 (en) 2009-07-31 2009-09-16 Medical House The Plc Improved autoinjector
BR112013002292A2 (pt) * 2010-09-14 2016-06-14 Hoffmann La Roche polipeptídeo du fusão, complexo de proteína, uso e kit
ES2708565T3 (es) * 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
JP7235676B2 (ja) 2017-05-17 2023-03-08 ザ ジェネラル ホスピタル コーポレイション 結節性硬化症の遺伝子治療

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE159548T1 (de) 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
JPH05505112A (ja) * 1990-11-27 1993-08-05 バイオジェン，インコーポレイテッド Ａｉｄｓ、ａｒｃおよびｈｉｖ感染の予防および治療に有用な抗ｃｄ４抗体ホモログ
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CZ289472B6 (cs) 1991-07-25 2002-01-16 Idec Pharmaceuticals Corporation Chimérická protilátka, nukleová kyselina, která ji kóduje, způsob její produkce a farmaceutická kompozice, která ji obsahuje
ES2139017T3 (es) * 1992-07-20 2000-02-01 Univ Duke Compuestos que inhiben la replicacion del vih.
WO1994028143A1 (en) 1993-05-21 1994-12-08 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
DE69627665T2 (de) 1995-05-18 2004-02-19 Ortho-Mcneil Pharmaceutical, Inc. Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti-cd4-antikoepern
US6743594B1 (en) * 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6475491B1 (en) 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
AU3375697A (en) * 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
CA2256306C (en) 1996-06-03 2011-03-29 United Biomedical, Inc. Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
US6020159A (en) 1996-09-24 2000-02-01 Smithkline Beecham Corporation 3-dehydroquinate synthase
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US5888809A (en) * 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6020495A (en) * 1997-12-08 2000-02-01 Pharm-Eco Laboratories, Inc. Stereoselective method for synthesizing dolaphenine
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
US6610834B1 (en) * 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
EP1144006B1 (en) 1998-12-16 2007-10-17 Progenics Pharmaceuticals, Inc. CCR5 Antibody PA14
ATE286074T1 (de) 1999-03-11 2005-01-15 Micromet Ag Gegen ccr5 gerichtete antikörperkonstrukte und ihre verwendung in der behandlung von autoimmunkrankheiten
EP2110381A1 (en) * 1999-05-17 2009-10-21 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US6692745B2 (en) * 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
KR20030032916A (ko) * 2000-02-09 2003-04-26 휴먼 게놈 사이언시즈, 인크. Ｃｃｒ5에 대한 항체
US20040043033A1 (en) * 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US7005503B2 (en) * 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
EP1207202A1 (en) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
US20020147147A1 (en) * 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
ES2525317T3 (es) * 2001-06-15 2014-12-22 F. Hoffmann-La Roche Ag Producción recombinante de inhibidores de la fusión antivirales peptídicos
CA2463931A1 (en) 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
NZ561465A (en) 2002-02-22 2009-04-30 Pdl Biopharma Inc Anti-CCR5 antibody
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
JP2007517522A (ja) 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof

Also Published As

Publication number Publication date
EP2118125B1 (en) 2011-10-26
US20090143288A1 (en) 2009-06-04
TW200902544A (en) 2009-01-16
BRPI0808732A2 (pt) 2014-08-12
IL199718A0 (en) 2010-04-15
JP2010520868A (ja) 2010-06-17
CL2008000707A1 (es) 2008-09-22
KR20090115867A (ko) 2009-11-09
ES2374962T3 (es) 2012-02-23
CN101616929B (zh) 2013-08-14
AU2008226051B2 (en) 2012-05-24
MX2009009370A (es) 2009-09-14
CN101616929A (zh) 2009-12-30
EP2118125A1 (en) 2009-11-18
PE20090163A1 (es) 2009-03-12
ATE530564T1 (de) 2011-11-15
JP5081931B2 (ja) 2012-11-28
KR101182951B1 (ko) 2012-09-13
CA2679647A1 (en) 2008-09-18
WO2008110332A1 (en) 2008-09-18
AU2008226051A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
EP3058954A3 (en) Immunogenic compositions and methods
EA201790871A1 (ru) Нацеленные конъюгатные композиции xten и способы их получения
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
GT200900121A (es) Moleculas de enlace de lingo y uso farmaceutico
CO6531435A2 (es) Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
EP2594581A3 (en) Peptide vaccines with Seq Id No: 178, 174, 186 or 194 for cancers expressing tumor-associated antigens
DE602007011901D1 (de) Ptiden und zellpenetrierenden peptiden gekoppelt a
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
EA201591213A1 (ru) Вакцины против вируса гепатита b
RU2015101081A (ru) Стабилизированный gp120
BR112012013139A2 (pt) oligopeptídeos imp-3 e vacinas incluindo os mesmos
AR065688A1 (es) Conjugados de peptidos antifusogenicos
RU2017132324A (ru) Иммуноконъюгаты для специфической индукции цитотоксичности т-клеток против клеток-мишеней
WO2008129422A8 (en) Demannosylated recombinant factor viii for the treatment of patients with haemophilia a
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding

Legal Events

Date Code Title Description
FB Suspension of granting procedure